Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2019-09-13 Director's Dealing
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-09-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text mentions a press release and a corporate presentation being furnished as exhibits. The document is relatively short (3603 characters) and primarily serves to announce the issuance of a press release and a corporate presentation, rather than containing detailed financial data or the full presentation itself. The key phrase 'The Company does not undertake to update the Presentation' and the furnishing of exhibits indicate this is an announcement of information rather than the information itself. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-08-12 English
SC 13D
Major Shareholding Notification
2019-07-29 English
SC 13D
Major Shareholding Notification
2019-07-29 English
SC 13D
Major Shareholding Notification
2019-07-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the completion of an asset sale, change in the company's independent registered public accounting firm, and related disclosures. It references an Asset Purchase Agreement and a letter from the previous auditor. There are no detailed financial statements or comprehensive financial analysis present, only announcements of corporate events and changes. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into more specific categories. The document length (7596 characters) and content confirm it is not a full annual or quarterly report, nor an earnings release or management discussion. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-07-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.